Navigation Links
Tumor budding identified as predictor for unfavorable outcome in lung cancer
Date:8/31/2010

Lung cancer is the leading cause of cancer deaths worldwide, and the prognosis is generally poor, even if surgery is successful. Furthermore, the incidence of one type of lung cancer, adenocarcinoma, has been increasing in recent years. A better understanding of the changes in tumor cell biology that result in a more aggressive neoplastic phenotype (characteristic of an abnormal mass of tissue) that have been completely surgically removed may help identify patients at risk for recurrent disease and lead to the development of more effective therapeutic treatments. Tumor budding is one such characteristic that may provide insights on advancing the understanding of recurrence.

The term tumor budding refers to single cells or small clusters of up to four cells within the stromal tissue at the invasive margin of colorectal cancers. This morphologic feature is increasingly being recognized as an adverse prognostic factor. To progress in this understanding, a study featured in the September edition of the Journal of Thoracic Oncology (JTO) conducted the first study to evaluate tumor budding in adenocarcinoma of the lung.

In order to investigate the relationship between tumor budding and the prognostic significance, researchers reviewed the cases of 201 consecutive patients who had undergone complete resection of adenocarcinoma of the lung measuring ≤ 30 mm( 1.25 inches) in diameter. The presence of tumor budding was significantly associated with lymph node metastasis, pathologic stage, vascular invasion, lymphatic invasion, and pleural invasion. Furthermore, the overall five-year survival rates of the group with budding and the group without budding was 67.5 and 88.3 percent, respectively, and the difference was significant.

"Overall, the pilot study identified that tumor budding is a distinct morphologic feature that has biologic and prognostic significance; moreover, the presence was identified as a significant predictor of an unfavorable outcome," explained lead investigator, Yoko Yamaguchi, MD. "Justifiably, clarification of the molecular mechanism that causes budding in lung adenocarcinoma will be important in the future."


'/>"/>

Contact: Colleen Butz
cbutz@spectrumscience.com
202-587-2557
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation
2. With muscle-building treatment, mice live longer even as tumors grow
3. Lung stem cells vital to lung repair associated with poor cancer prognosis when found in tumor
4. A lethal brain tumors strength may be a weakness as well
5. Merlin protein found to control liver stem cells, prevent tumor development
6. New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer
7. NIH award will enable design of brain tumor treatment that captures migrating cancer cells
8. New diagnostic chip able to generate single-cell molecular fingerprints for brain tumors
9. Iron oxide nanoparticles becoming tools for brain tumor imaging and treatment
10. LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI
11. Key pathway in end-stage prostate cancer tumor progression blocked
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... While ... Enovate Medical has introduced an innovative workstation designed to reduce nursing fatigue while ... Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to the ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... is Dr. Carol Francis' goals for each and every seminar, session ... Carol Francis will demonstrate five different brainwave tools which help energize creativity, focus ...
(Date:2/17/2017)... Austin, Tx (PRWEB) , ... February 17, 2017 ... ... of revenue cycle management services, announced today that Karen Pilley has been promoted ... expenses is critical in today’s shifting healthcare paradigm – a shift that demands ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... Teaching nursing care of vulnerable children is the focus ... is being created with the support of the Hearst Foundations. An initiative of the ... address what has been identified as a critical gap in preparing the next generation ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... YORK , Feb. 17, 2017  BioDigital, ... today the partnership of their 3D body mapping ... healthcare IT.  The new integration will be used ... an interactive model of the human body. BioDigital ... saves clinicians time, while also increasing the precision ...
(Date:2/16/2017)... Research and Markets has announced the ... Technologies" report to their offering. ... Traditional medical devices include ... non-drug coated implantables, large endoscopes, needle based drug delivery, lab ... last two to three decades for the treatment and management ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
Breaking Medicine Technology: